[go: up one dir, main page]

NO980016L - Macrolides - Google Patents

Macrolides

Info

Publication number
NO980016L
NO980016L NO980016A NO980016A NO980016L NO 980016 L NO980016 L NO 980016L NO 980016 A NO980016 A NO 980016A NO 980016 A NO980016 A NO 980016A NO 980016 L NO980016 L NO 980016L
Authority
NO
Norway
Prior art keywords
positions
acid residue
macrocyclic ring
macrolides
iii
Prior art date
Application number
NO980016A
Other languages
Norwegian (no)
Other versions
NO980016D0 (en
Inventor
Theodor Fehr
Lukas Oberer
Valerie Quesniaux Ryffel
Jean-Jacques Sanglier
Walter Schuler
Richard Sedrani
Original Assignee
Ciba Geigy Ag
Novartis Erfind Verwalt Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9513596.8A external-priority patent/GB9513596D0/en
Priority claimed from GBGB9515495.1A external-priority patent/GB9515495D0/en
Application filed by Ciba Geigy Ag, Novartis Erfind Verwalt Gmbh filed Critical Ciba Geigy Ag
Publication of NO980016D0 publication Critical patent/NO980016D0/en
Publication of NO980016L publication Critical patent/NO980016L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/465—Streptomyces

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • General Engineering & Computer Science (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

En ny klasse av makrolider, der i) posisjonene 2 til og med 6 av den makrocykliske ringen blir tilveiebragt med en pipe- ridazinylkarboksylsyrerest; og/eller ii) posisjonene 7 til og med 9 av den makrocykliske ringen blir tilveiebragt med en aro- matisk a-aminosyrerest; og/eller iii) posisjonene 10 til og med 12 av den makrocykliske ringen blir tilveiebragt med en alifatisk a-aminosyrerest, omfatter fortrinnsvis to, eller særlig alle tre av de karakteristiske strukturtrekkene i), ii) og iii), mer spesifikt en forbindelse med formel IXA new class of macrolides, wherein i) positions 2 through 6 of the macrocyclic ring are provided with a piperidazinylcarboxylic acid residue; and / or ii) positions 7 through 9 of the macrocyclic ring are provided with an aromatic α-amino acid residue; and / or iii) positions 10 through 12 of the macrocyclic ring are provided with an aliphatic α-amino acid residue, preferably comprising two, or more particularly all three of the characteristic structural features i), ii) and iii), more specifically a compound having formula IX

NO980016A 1995-07-04 1998-01-02 Macrolides NO980016L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9513596.8A GB9513596D0 (en) 1995-07-04 1995-07-04 Organic compounds
GBGB9515495.1A GB9515495D0 (en) 1995-07-28 1995-07-28 Organic compounds
PCT/EP1996/002952 WO1997002285A1 (en) 1995-07-04 1996-07-04 Macrolides

Publications (2)

Publication Number Publication Date
NO980016D0 NO980016D0 (en) 1998-01-02
NO980016L true NO980016L (en) 1998-03-02

Family

ID=26307320

Family Applications (1)

Application Number Title Priority Date Filing Date
NO980016A NO980016L (en) 1995-07-04 1998-01-02 Macrolides

Country Status (17)

Country Link
EP (1) EP0836616A1 (en)
JP (1) JPH11509092A (en)
KR (1) KR19990028724A (en)
CN (1) CN1193979A (en)
AR (1) AR006514A1 (en)
AU (1) AU708004B2 (en)
BR (1) BR9609324A (en)
CA (1) CA2224715A1 (en)
CO (1) CO4750713A1 (en)
CZ (1) CZ424297A3 (en)
HU (1) HUP9802320A3 (en)
IL (1) IL122844A0 (en)
NO (1) NO980016L (en)
PL (1) PL324346A1 (en)
SK (1) SK498A3 (en)
TR (1) TR199800001T1 (en)
WO (1) WO1997002285A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6124453A (en) * 1995-07-04 2000-09-26 Novartis Ag Macrolides
GB9811854D0 (en) * 1998-06-02 1998-07-29 Ciba Geigy Ag Organic compounds
US7368423B1 (en) * 2001-12-05 2008-05-06 The Scripps Research Institute Composition and method for treating chronic allograft rejection
EP2583678A3 (en) 2004-06-24 2013-11-13 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
CN101242842A (en) 2005-06-17 2008-08-13 诺瓦提斯公司 Use of SANGLIFEHRIN in HCV
US8067024B2 (en) 2006-02-10 2011-11-29 Medtronic Vascular, Inc. Medical devices to prevent or inhibit restenosis
CN101289440B (en) * 2007-06-29 2010-08-25 中国热带农业科学院热带生物技术研究所 Polyene macrocyclic compounds, preparation thereof and applications
US8962329B2 (en) 2008-09-24 2015-02-24 Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences Gene cluster
WO2011098805A1 (en) 2010-02-09 2011-08-18 Biotica Technology Limited Sanglifehrin based compounds
WO2011098808A1 (en) 2010-02-09 2011-08-18 Biotica Technology Limited Sanglifehrin based compounds
BR112012019866A8 (en) 2010-02-09 2017-12-26 Biotica Tech Limited COMPOUND, USE THEREOF, PHARMACEUTICAL COMPOSITION, AND PROCESS FOR PREPARING A COMPOUND
GB201008123D0 (en) 2010-05-17 2010-06-30 Biotica Tech Ltd Novel compounds
AR084217A1 (en) 2010-12-10 2013-05-02 Gilead Sciences Inc MACROCICLIC INHIBITORS OF VIRUS FLAVIVIRIDAE
EP2654753B1 (en) * 2010-12-20 2018-10-31 Neurovive Pharmaceutical AB Sanglifehrin derivatives and methods for their production
JO3063B1 (en) 2011-03-29 2017-03-15 Neurovive Pharmaceutical Ab Innovative compound and methods for its production
GB201118334D0 (en) 2011-10-24 2011-12-07 Biotica Tech Ltd Novel dosage form
JP6209600B2 (en) 2012-06-08 2017-10-04 ギリアード サイエンシーズ， インコーポレイテッド Macrocyclic inhibitors of flaviviridae viruses
MX2014014766A (en) 2012-06-08 2015-05-11 Gilead Sciences Inc Macrocyclic inhibitors of flaviviridae viruses.
AR091279A1 (en) 2012-06-08 2015-01-21 Gilead Sciences Inc MACROCICLIC INHIBITORS OF VIRUS FLAVIVIRIDAE
BR112019009903A2 (en) 2016-11-18 2019-08-13 Neurovive Pharmaceutical Ab sangliferin analog, combination, pharmaceutical composition, and method for treating a subject suffering from cancer or B-cell malignancy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9318144D0 (en) * 1993-09-01 1993-10-20 Sandoz Ltd Organic compounds
WO1995015328A1 (en) * 1993-11-30 1995-06-08 Abbott Laboratories Macrocyclic immunomodulators with novel cyclohexyl ring replacements

Also Published As

Publication number Publication date
MX9800217A (en) 1998-07-31
PL324346A1 (en) 1998-05-25
CN1193979A (en) 1998-09-23
SK498A3 (en) 1998-07-08
CZ424297A3 (en) 1998-04-15
HUP9802320A3 (en) 1999-03-29
AU708004B2 (en) 1999-07-29
AR006514A1 (en) 1999-09-08
AU6519396A (en) 1997-02-05
TR199800001T1 (en) 1998-04-21
CO4750713A1 (en) 1999-03-31
WO1997002285A1 (en) 1997-01-23
CA2224715A1 (en) 1997-01-23
EP0836616A1 (en) 1998-04-22
HUP9802320A2 (en) 1999-02-01
JPH11509092A (en) 1999-08-17
KR19990028724A (en) 1999-04-15
BR9609324A (en) 1999-05-25
NO980016D0 (en) 1998-01-02
IL122844A0 (en) 1998-08-16

Similar Documents

Publication Publication Date Title
NO980016L (en) Macrolides
WO2002003984A3 (en) Anticonvulsant derivatives useful for treating and preventing the development of type ii diabetes mellitus and syndrome x
NO983487D0 (en) Derivatives of camptothecin for use in the treatment of cancer
TW288011B (en)
TW337977B (en) Low VOC liquid formulations of 1, 2-benzisothiazolin-3-one and method of manufacture
ATE69239T1 (en) OLIGOPEPTIDYLNITRILE DERIVATIVES, AGENTS CONTAINING THEM, PROCESSES FOR THEIR PREPARATION AND THEIR USE.
DK0518558T3 (en) 1-methylcarbapenem derivatives, their preparation and their use as antibiotics
WO1999003817A3 (en) Aliphatic propargylamines as cellular rescue agents
CA2267945A1 (en) Anticonvulsant derivatives useful in treating neuropathic pain
CA2023089A1 (en) Method for the treatment of cardiac and of vascular hypertrophy and hyperplasia
NO932431L (en) PROCEDURE AND INTERMEDIATES FOR THE MANUFACTURE OF AZABICYCLO (2,2,2) OCTAN-3-IMINES
DE60006825D1 (en) SEROTONERGE BENZOFURANE
ES2000908A6 (en) Nematocidal agents.
FR2642755B1 (en)
ATE290574T1 (en) COLOR PREPARATIONS
ZA9410287B (en) N-oxides of 4-arylpiperazines and 4-arylpiperidines
CA2144344A1 (en) Cyclic benzylamino, benzylamido and benzylimido derivatives as antipsychotic agents
BG104302A (en) Method for preparing substituted 4-phenyl-4-cyanocyclohexanoic acids
ZA872664B (en) Six-membered heterocyclic derivatives of n'-substituted-n,n'-diacylhydrazines
CA2011642A1 (en) Benzoxazine dyes
EA199900684A1 (en) Iminoazanthracyclinone derivatives for the treatment of amyloidosis
NO983527L (en) Dihydrobenzofuran and related compounds useful as anti-inflammatory agents
TW334337B (en) Preparation and composition for a compound of controlling and preventing phytopathogenic fungi
HK79595A (en) Heterocyclic pigments
CA2236073A1 (en) Intimal thickening inhibitory agent